Archive

Gastrointestinal Cancers Symposium Daily News Archive

The Gastrointestinal Cancers Symposium Daily News is the official news source for the Gastrointestinal Cancers Symposium, providing expert perspectives on controversial topics and session highlights. Articles include physician-authored “Expert Editorials” on current clinical issues in oncology, interviews with Meeting attendees, and recaps of key sessions and presentations. Content is current as of the Meeting date and may not reflect the most recent data.

February 7, 2017

test

Read more

January 22, 2017

Investigators dug back into the Adenoma Prevention With Celecoxib (APC) tissue archives to identify biomarkers that distinguish those individuals at high risk for colorectal adenomas who stand to derive greatest benefit from celecoxib chemoprevention.

Read more

January 21, 2017

Inhibiting both BRAF and EGFR within the MAPK pathway proves promising for staunching tumor growth in select cases of metastatic colorectal cancer based on interim results of the phase II SWOG S1406 trial.

Read more

January 21, 2017

Findings from a prospective phase II trial suggest that treatment with cabozantinib monotherapy confers marked clinical benefit in patients with progressive, well-differentiated neuroendocrine tumors—lesions that historically are difficult to treat given their chemoresistant nature.

Read more

January 21, 2017

Preliminary data from the phase I/II CheckMate 040 study of nivolumab suggest that the anti-PD-1 antibody is both active and well tolerated when given as first- or second-line monotherapy to patients with advanced HCC.

Read more

January 21, 2017

Level I evidence supporting the benefit of adjuvant therapy in localized biliary cancer remains elusive based on the negative results of the PRODIGE 12–ACCORD 18 trial that compared GEMOX versus surveillance.

Read more

January 21, 2017

Results of this small feasibility study suggest that stereotactic body radiation therapy may be an alternative bridging option for patients with locally advanced disease—one that can be performed in the outpatient setting while potentially causing minimal major morbidity.

Read more

January 20, 2017

Nivolumab represents the first immunotherapy in phase III analyses to significantly improve OS, PFS, and ORR in patients with advanced gastric or gastroesophageal junction cancer, fulfilling a dire need for effective salvage therapy for a subgroup of patients.

Read more

January 19, 2017

This phase II trial demonstrates that using PET imaging following initial induction chemotherapy to assess early response can maximize pCR rates in esophageal adenocarcinoma by signaling the need to switch from ineffective to alternative chemotherapy during preoperative chemoradiation.

Read more
January 12, 2017

Listen to the latest ASCO Daily News podcast.

Read more
January 12, 2017

ASCO has launched its first scientific journal dedicated to precision oncology. It will be published as articles become available and is currently accepting original clinical research, scientific reviews, and editorials.

Read more
January 12, 2017

ASCO has been working to provide resources and information to help oncology practices prepare for the reimbursement and care delivery changes under MACRA.

Read more

January 12, 2017

Drs. Geoffrey Y. Ku and David H. Ilson discuss recent phase III studies that have attempted to refine the role of perioperative strategies in the treatment of gastric cancer.

Read more

January 12, 2017

As the worldwide death rate from hepatobiliary cancers continues to grow, Drs. Karasic and Loaiza-Bonilla explain that research must focus on finding an effective treatment—and immunotherapy could be the answer. 

Read more

January 12, 2017

Dr. Jorge Gallardo and colleagues discuss the epidemiology of esophageal, gastric, liver, gallbladder, pancreatic, colon, and rectal cancers in Chile and how the country’s changing demographics across the past 20 years have increased cancer mortality rates.

Read more

January 12, 2017

As of November 15, 2016, more than 100 participants have been enrolled on a study drug as part of ASCO’s Targeted Agent and Profi ling Utilization Registry Study.

Read more

January 12, 2017

Dr. Christopher Lieu discusses his phase I trial on a combination therapy of MEK and Wnt inhibitors to treat RAS-mutant colorectal cancer.

Read more
January 12, 2017

ASCO’s Quality Training Program will now be held at regional locations. 

Read more